Disclosures for "12-month Effectiveness and Tolerability of Brivaracetam in Patients with Epilepsy and Cognitive or Psychiatric Comorbidities: Subgroup Data from the International EXPERIENCE Pooled Analysis"
-
Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW pharmaceutical. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW pharma. Vicente Villanueva has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Arvelle.
-
Dr. D'Souza has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LivaNova, Eisai, UCB, Tilray. Dr. D'Souza has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB Pharma, Eisai Pharmaceutical. Dr. D'Souza has stock in Epiminder. The institution of Dr. D'Souza has received research support from UCB Pharma. The institution of Dr. D'Souza has received research support from Eisai Pharmaceutical.
-
Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gideon, Essary, Tardio and Carter PLC, Nashville TN TN law firm. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Friedman Dazio and Zulanas Law Firm Birmingham AL. The institution of Dr. Faught has received research support from UCB Pharma.
-
The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Sience. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alliance. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle Therapeutics. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Aquestive. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Klein has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for PrevEp. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Fenwick . Dr. Klein has received research support from DOD/CURE.
-
Markus Reuber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angellini Pharma. Markus Reuber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharma. Markus Reuber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. The institution of Markus Reuber has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA MedTech. Markus Reuber has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Markus Reuber has received research support from UCB Pharma. Markus Reuber has received publishing royalties from a publication relating to health care.
-
Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle. Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI. Felix Rosenow has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW Pharmaceuticals. The institution of Felix Rosenow has received research support from EISAI. Felix Rosenow has received publishing royalties from a publication relating to health care.
-
Javier Salas-Puig has nothing to disclose.
-
Dr. Soto Insuga has nothing to disclose.
-
Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini Pharma. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Desitin Arzneitmittel. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Marinus. Adam Strzelczyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GW/Jazz pharmaceuticals. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UNEEG. Adam Strzelczyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB Pharma (Zogenix). Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bicodex.
-
Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gidley, Sarli & Marusak, LLP. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea.
-
Dr. Besson has received personal compensation for serving as an employee of UCB.
-
Dr. Bourikas has nothing to disclose.
-
Tony Daniels has received personal compensation for serving as an employee of UCB . Tony Daniels has received stock or an ownership interest from UCB.
-
Dr. Floricel has received personal compensation for serving as an employee of UCB Biosciences GmbH. Dr. Floricel has received stock or an ownership interest from UCB Biosciences GmbH.
-
Mr. Friesen has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for UCB.
-
Dr. Laloyaux has received personal compensation for serving as an employee of UCB.
-
Dr. Sendersky has received personal compensation for serving as an employee of UCB.
-
Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Bernhard Steinhoff has received personal compensation in the range of $0-$499 for serving as a Consultant for B.Braun Melsungen. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuraxpharm. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Precisis. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle. Bernhard Steinhoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Bernhard Steinhoff has received research support from UCB. The institution of Bernhard Steinhoff has received research support from Eisai. The institution of Bernhard Steinhoff has received research support from SK LIfe Science.